- Price is above Fair Value, showing premium demand versus the model.
- Volume is elevated versus the 13-week average, confirming attention.
ALMR
NASDAQ
Week ended 18 Sep 2026
Weekly Investor Report
Alamar Biosciences, Inc. Common Stock · Healthcare · Medical Devices
Latest close
34.85 USD
25.0%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is - below the Trend Line and sits at 81.3% of its 52-week range. The latest completed week returned 25.0%, after a 1.8% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 50/100. Near-term considerations: earnings are due in 50d.
Setup score
47
out of 100
Latest Close
34.85 USD
18 Sep 2026
1W Return
25.0%
latest completed week
4W Return
1.8%
short-term follow-through
12W Return
30.7%
quarterly tape
Trend Breadth
0.0%
0 of 23 weeks active
Volume Ratio
2.2x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Activity pressure is negative, which weakens the current setup.
- 6 reversal markers appear in the recent smart-money tape.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
25.0%
Latest completed week; four-week move 1.8%.
Indicator stack
0/50
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
50/100
5 relevant articles in the latest sentiment read.
Event risk
50d
Next report is scheduled for 09 Nov 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is - below the Trend Line and sits at 81.3% of its 52-week range. The latest completed week returned 25.0%, after a 1.8% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 2.2x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
14 Aug
21 Aug
28 Aug
4 Sep
11 Sep
18 Sep
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.4612-week average 0.26
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.46Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers66 reversal markers
No recent accumulation markers. 6 reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 1.8% over four weeks, 30.7% over 12 weeks, and - over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.00Latest activity-pressure read.
Pressure change-Four-week change in activity pressure.
Leadership-Latest relative-leadership reading.
RS change-Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 11 Sep 2026
Financial statements through 31 Dec 2025
Field coverage 70%
Model confidence 52%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength34/100Blend of value, momentum, and quality. Underlying universe rank 67; rank 1 is best.
Value42/100Relative valuation strength. Underlying universe rank 59; rank 1 is best.
Quality40/100Profitability and accounting quality. Underlying universe rank 61; rank 1 is best.
Momentum42/100Medium-term price momentum. Underlying universe rank 59; rank 1 is best.
Growth42/100Revenue and earnings growth. Underlying universe rank 59; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 26.1x Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -3.2% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 56.2% Gross profit retained from each unit of revenue.
- Operating margin
- -42.2% Operating profit retained from revenue.
- Free-cash-flow margin
- -80.8% Free cash flow generated from revenue.
- Return on invested capital
- -10.2% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 195.2% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 5/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -0.1% Net share repurchases relative to market value.
- Shareholder yield
- -0.1% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 3.0x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment50/100
Weighted news tone is neutral across 5 relevant articles.
1 positive · 3 neutral · 1 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings50dNext report is scheduled for 09 Nov 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-9.6%Distance below the 52-week high.
13-week volatility11.3%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
17 Apr
15 May
12 Jun
10 Jul
7 Aug
4 Sep
18 Sep
Weeks higher12 of 2210 weeks finished lower.
Best week+25.0%Week of 18 Sep.
Worst week-10.3%Week of 28 Aug.
Latest week+25.0%Week of 18 Sep.
Shape of recent returns
Strong gains7
Modest gains5
Flat weeks0
Modest losses4
Sharp losses6
Recent vol11.3%13-week weekly-return volatility.
Base vol10.0%52-week weekly-return volatility.
Up/down split12/10Count of positive and negative weeks in the 52-week window.
Average skew9.5% / -5.8%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average-2.8%
Trend breadth69.0%
Trend69.0%active weekly trend signals
MD68.0%positive activity pressure
RS49.0%positive relative leadership
Four-week leaders
IndustryUS Medical Devices
4-week rank17 / 100
Group average-5.4%
Trend breadth45.0%
Trend45.0%active weekly trend signals
MD53.0%positive activity pressure
RS32.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape38/100
Trend, activity pressure, participation, and risk combine to a 38/100 tape read.
Indicator analysis9/100Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.
Activity pressure 0.46; 6 reversal markers Factors38/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 80; Small Cap Core rank 61 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment50/100Weighted news tone is neutral across 5 relevant articles.
Alamar Biosciences, Inc. Common Stock (NASDAQ: ALMR) Stock Price, News & Analysis Insiders50/100No recent insider transaction evidence is stored.
Earnings50dNext report is scheduled for 09 Nov 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 18 Sep 2026 | 34.85 USD | 25.0% | - | 26.15 USD | 0.00 | - | 3.9M | Off |
| 11 Sep 2026 | 27.89 USD | -9.4% | - | 25.76 USD | 0.00 | - | 1.1M | Off |
| 4 Sep 2026 | 30.80 USD | 0.3% | - | 25.65 USD | 0.00 | - | 1.1M | Off |
| 28 Aug 2026 | 30.71 USD | -10.3% | - | 25.40 USD | 0.00 | - | 1.7M | Off |
| 21 Aug 2026 | 34.24 USD | 3.3% | - | 25.12 USD | 0.00 | - | 1.6M | Off |
| 14 Aug 2026 | 33.16 USD | 16.5% | - | 24.61 USD | 0.00 | - | 2.9M | Off |
| 7 Aug 2026 | 28.46 USD | 12.2% | - | 24.11 USD | 0.00 | - | 1.0M | Off |
| 31 Jul 2026 | 25.36 USD | -2.0% | - | 23.84 USD | 0.00 | - | 962.2K | Off |
| 24 Jul 2026 | 25.88 USD | -0.3% | - | 23.73 USD | 0.00 | - | 977.2K | Off |
| 17 Jul 2026 | 25.95 USD | -8.7% | - | 23.58 USD | 0.00 | - | 1.5M | Off |
| 10 Jul 2026 | 28.42 USD | 9.6% | - | 23.40 USD | 0.00 | - | 1.0M | Off |
| 3 Jul 2026 | 25.94 USD | -2.7% | - | 22.98 USD | 0.00 | - | 1.9M | Off |
| 26 Jun 2026 | 26.67 USD | 21.4% | - | 22.71 USD | 0.00 | - | 3.4M | Off |
| 19 Jun 2026 | 21.96 USD | -0.2% | - | 22.32 USD | 0.00 | - | 1.6M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.